Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat Food Effect and Chewing Bioavailability Study
NCT06418620Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of venglustat in Fabry disease (FD), Gaucher disease (GD), GM2 gangliosidosis and 2 more (3 arms), sponsored by Sanofi. Primary endpoints: Maximum Plasma Concentration, Area Under the Plasma Concentration-Time Curve to Last Quantifiable Concentration and 1 more. Started Jun 2020; status: completed.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)Gaucher disease (GD)GM2 gangliosidosisautosomal dominant polycystic kidney disease (ADPKD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06418620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06418620.